Hlscience에이치엘사이언스

Hlscience is still loss-making with revenue shrinking for several years, and its share price has fallen about 47% over the past year.

Hlscience is a bio-healthcare company selling health functional foods, quasi-drugs, microbiome products and genetic testing, mainly through TV home shopping, e-commerce and overseas buyers. Over the trailing twelve months to H1 2026 it reported revenue of ₩10.4B against an operating loss of ₩10.1B and a net loss of ₩11.2B. The share price closed at ₩5,210 on 2026-10-20, with a market cap of about ₩28.1B.

What stands out

• Revenue fell from ₩104.4B in 2021 to ₩16.7B in 2025, and the trailing twelve-month figure is lower still at ₩10.4B.
• Operating margin was -96.3% on a trailing basis, and free cash flow was -₩6.9B, so the business is burning cash.
• Cash of ₩1.7B is shown with no borrowings listed, and liabilities to equity is 2.8%, so debt is not a visible pressure in the data.
• The stock trades at 0.4 times book value and 2.7 times sales, with no earnings-based multiple because profits are negative.
• The 2026 filings are routine (half-year and quarterly reports, insider holding reports, AGM results), and the data contains no news headlines for the period.
• Foreign ownership slipped from 0.8% to 0.7% over 60 days, while 20-day flows show retail buying and foreign selling.

What to watch

• The next quarterly or annual results, to see whether revenue stabilises and losses narrow from the H1 2026 trend.
• Whether cash of ₩1.7B is enough to fund the ₩6.9B negative free cash flow without new financing, which the data does not address.
• Any future filings or news on the company's strategy, customers or overseas sales, since the data includes none beyond the filing titles listed.